A new world of treatment

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.
Contact Us

About

Adaptive Phage Therapeutics, Inc. (APT) is a clinical-stage company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria.

Technology

Two key components of APT's approach are 1) PhageBank™, a large and dynamically growing collection of bacteriophages or "phages" (viruses that attack specific targeted bacteria) and 2) an innovative rapid system for matching phage to patient-specific bacterial infections.

Success Story

In 2016 APT's approach achieved its first in-human success with the rescue of a critically ill MDR infected patient: Tom Patterson, multi-drug resistant Acinetobacter baumanii survivor.